Navigation Links
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Date:9/24/2009

"non-culprit" lesions of the three-vessel coronary tree. Half of the patients treated for non-culprit events exemplified the classic notion of vulnerable plaque.

The event rate, particularly that attributed to vulnerable plaques specifically, was lower than expected. Further, patients who experienced "non-culprit" events in the years following PCI were more likely to present with progressive or unstable angina, and rarely with cardiac death, arrest or MI. Imaging of the lesions that did progress to events suggests that vulnerable plaque lesions with a large plaque burden and large necrotic core without a visible cap were at especially high risk for future adverse cardiovascular events.

"Abbott's PROSPECT trial is the most comprehensive study ever done on vulnerable plaque and the results shed new light on understanding its role in the progression of coronary artery disease," said John M. Capek, executive vice president, medical devices, Abbott. "As a leader in cardiovascular devices, diagnostics and medicines, Abbott looks forward to sharing these results with the vascular community and adding to our understanding of the disease."

About the PROSPECT Trial

Abbott's PROSPECT trial is the first prospective natural history study to examine the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT used novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

PROSPECT enrolled 700 patients from 40 clinical centers across the United States and Europe. All patients received PCI for acute coronary syndrome (ACS), which included unstable angina, NSTEMI or STEMI. Patient follow up continued for three years. Abbott sponso
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
(Date:9/19/2014)...  CytRx Corporation (Nasdaq: CYTR ), a ... announced that David J. Haen , Vice President, ... the Biotech Industry Conference on Friday, September 26 th ... place at the Millennium Broadway Hotel in ... and archived webcast of the presentation will be available ...
(Date:9/19/2014)... VIENNA, Austria , September 19, 2014 ... glucose control persist for many years in people with ... to produce major long term benefits for the kidneys." ... control in patients with type 2 diabetes leads to ... to usual care. The global study has ...
Breaking Medicine Technology:Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Hope for Treatment of,Children, WHITE PLAINS, N.Y., Feb. ... rare craniofacial birth defect in,mice and holds promise to ... funded in part by the March of Dimes., ... Nature Medicine,demonstrates the potential for translating basic research into ...
... BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. ... "Company"), a,pharmaceutical company in the People,s Republic ... achieved significant milestones in the development of,isosorbide ... drug,for the prevention and treatment of angina., ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:9/21/2014)... the physical activity benefits of active play, a new ... children, playing has no goal it is an ... alone or with friends, and it represents "an opportunity ... boredom, sadness, fear, or loneliness." "By focusing on the ... aspects of play that are beneficial to young people,s ...
(Date:9/21/2014)... BC (PRWEB) September 21, 2014 Burnaby ... educational information to clients in order to help them ... sessions held at the clinic that will help clients ... they can also take active participation in the healing ... and posture, clients will be able to facilitate the ...
(Date:9/21/2014)... 2014 Over the past five years, ... inundate the market, thereby cutting into revenue growth for ... to data from Industry Canada, the loss of patent ... and $2.5 billion in 2010 and 2012, respectively. “In ... which has hampered revenue growth, many pharmaceutical manufacturers have ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
(Date:9/21/2014)... SUNDAY, Sept. 21, 2014 (HealthDay News) -- Young women ... and know which foods they should eat. But they ... nutritional choices, according to a new study. ... the University of Illinois,s Peer Education Exercising and Eating ... what would they choose to eat if they were ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News: College Women Can Use Food Strategies, Study Finds 2
... Oct. 8 Boston Scientific,(NYSE: BSX ) announced ... third quarter results, which it plans to report on ... a $250 million milestone,payment from Abbott Laboratories (NYSE: ... Guidant,s vascular intervention and endovascular,solutions businesses. As a result, ...
... Weight Watchers,International, Inc. (NYSE: WTW ) ... serve as its President, North America, effective November,3, ... product,operations and general management experience, will oversee the ... products,publishing and licensing businesses and will be reporting ...
... sometimes goes awry has been implicated in breast cancer. ... of the Notch pathway may contribute to breast cancer. ... Drs Jane Visvader and Geoff Lindeman from the Victorian ... Notch genes in regulating breast development and function. ...
... Bulletin Board:,VYTC) today announced that effective October 7, ... an independent scientific consultant to Vyta Corp.,Dr. Sorgente ... at,BIOAGRA, LLC, a joint venture, equally owned by ... 2008, Vyta Corp announced its filing of,foreclosure litigation ...
... 8 Mass casualty incidents --,such as terrorist ... or hurricanes -- raise the life-and-death reality that,existing ... for all who,need it. One of the most ... requiring respiratory support., Disaster specialists and health ...
... Tampa, FL (Oct. 8, 2008) Women, the elderly, ... are all less likely to receive same-day coronary angioplasty ... South Florida researchers found. Their study was published this ... Cardiology . , Angioplasty, also known as percutaneous ...
Cached Medicine News:Health News:Boston Scientific Announces Third Quarter Adjustments 2Health News:Boston Scientific Announces Third Quarter Adjustments 3Health News:Boston Scientific Announces Third Quarter Adjustments 4Health News:Boston Scientific Announces Third Quarter Adjustments 5Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 2Health News:Missouri Firm's New Ventilator Design Addresses Serious Homeland Security Issue 3Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 2Health News:Florida study finds barriers to angioplasty for life-threatening heart attacks 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: